MedTrace Logo

A Study of GR1803 in Systemic Lupus Erythematosus

NCT07348055 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-03-10

No results posted yet for this study

Summary

to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus

Conditions

  • Systemic Lupus Erthematosus
  • Auto Immune Disease

Interventions

BIOLOGICAL

GR1803 injection

step-up dosing, Dose and frequency according to the protocol

Sponsors & Collaborators

  • Genrix (Shanghai) Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2027-06-01
Completion
2027-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07348055 on ClinicalTrials.gov